News - RNF43 mutation

Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer. (PubMed, Gastroenterol Rep (Oxf))

Actionable gene fusions are more prevalent in MSI-H, RAS/BRAF wildtype, or RNF43-mutated CRC, as well as in colon cancer. Mapping of these molecular markers can markedly increase the fusion detection rate, which can help clinicians select candidates for fusion testing and targeted therapy.

1 month ago

Journal • MSi-H Biomarker

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RNF43 (Ring Finger Protein 43) • NTRK (Neurotrophic receptor tyrosine kinase)

MSI-H/dMMR • BRAF mutation • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • BRAF wild-type • RAS mutation • RNF43 mutation • NTRK fusion

Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study. (PubMed, EBioMedicine)

The combination of genomic and transcriptomic analyses of primary pancreatic tumours enables us to distinguish metastatic tumours from other tumour types. Our molecular strategy may assist in predicting overall survival outcomes for platinum or gemcitabine-based chemotherapies, as well as radio-chemotherapy.

1 month ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • RNF43 (Ring Finger Protein 43)

TP53 mutation • KRAS mutation • HRD • TP53 wild-type • RNF43 mutation

gemcitabine

2ms

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (clinicaltrials.gov)

P1, N=185, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

2 months ago

Trial completion

BRAF (B-raf proto-oncogene) • RNF43 (Ring Finger Protein 43)

BRAF mutation • RNF43 mutation

spartalizumab (PDR001) • WNT974

2ms

Prognostic determinants in cancer survival: a multidimensional evaluation of clinical and genetic factors across 10 cancer types in the participants of Genomics England's 100,000 Genomes Project. (PubMed, Discov Oncol)

This study provides a comprehensive view of clinicopathological and genetic prognostic factors across different cancer types and draws attention to less commonly known factors which might help produce more precise prognosis and survival estimates. The results from this study contribute to the understanding of cancer disease and could be used by researchers to develop complex prognostic models, which in turn could help predict cancer prognosis more accurately and improve patient outcomes.

2 months ago

Journal • Tumor mutational burden

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • MSH6 (MutS homolog 6) • RNF43 (Ring Finger Protein 43) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CDH1 (Cadherin 1) • FANCE (FA Complementation Group E) • GATA3 (GATA binding protein 3)

TP53 mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • NF1 mutation • RNF43 mutation

2ms

TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases. (PubMed, Heliyon)

Gene signatures, such as TP53 or EGFR amplification, were associated with worse survival in patients diagnosed with NSCLC-BM. These valuable findings may shed light on new strategies for the prognostic assessment of specific patient groups.

2 months ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43)

TP53 mutation • EGFR amplification • RNF43 mutation • TP53 amplification

2ms

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration. (PubMed, Cancer Immunol Immunother)

This retrospective real-world study confirmed the clinical benefit of durvalumab plus chemotherapy in treatment-naïve ABC patients. Peripheral sPD-L1 and CSF1R are promising prognostic biomarkers for this therapeutic strategy. Presence of ADGRB3 or RNF43 mutations could improve the stratification of immunotherapy outcomes, but further studies are warranted to explore the underlying mechanisms.

2 months ago

Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases

RNF43 (Ring Finger Protein 43) • CSF1R (Colony stimulating factor 1 receptor) • ADGRB3 (Adhesion G Protein-Coupled Receptor B3)

RNF43 mutation

Imfinzi (durvalumab) • gemcitabine

5ms

RNF43-mutations are associated with stronger antitumour immune responses and improved outcomes in pancreatic cancer (ECP 2024)

RNF43mut cases show improved clinical outcomes and stronger antitumour immune responses than RNF43wt cases in MSSPDACs. Moreover, RNF43-mutations were significantly more frequent in MSI-PDACs. Our results underscore the need for deeper understanding of molecular factors modulating the biological behaviour and treatment response of PDACs that can help refining the stratification and optimizing the clinical management of patients.

5 months ago

Tumor mutational burden

TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • RNF43 (Ring Finger Protein 43) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)

TMB-H • RNF43 mutation

Oncomine Tumor Mutation Load Assay

6ms

Molecular characteristics of early-onset compared with late-onset colorectal cancer: A case controlled study. (PubMed, Int J Surg)

This study revealed a significantly higher MSI-H distribution rate in early-onset colorectal cancer, and EOCRC exhibits a distinct mutational signature coupled with higher PD-L1 expression. These findings hold promise in guiding personalized therapeutic strategies for improved disease management in EOCRC patients.

6 months ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • FAT1 (FAT atypical cadherin 1) • CASP8 (Caspase 8) • FANCI (FA Complementation Group I) • KMT2B (Lysine Methyltransferase 2B) • DPYD (Dihydropyrimidine Dehydrogenase)

PD-L1 expression • MSI-H/dMMR • ATM mutation • ARID1A mutation • PBRM1 mutation • RNF43 mutation • KMT2B mutation • FANCI mutation

6ms

Novel insights into tumorigenesis revealed by molecular analysis of Lynch syndrome cases with multiple colorectal tumors. (PubMed, Front Oncol)

Somatic variants in APC and CTNNB1 were unique to each tumor. Frequent somatic RNF43 hot spot variants combined with SBS96 signature and increased tendency to DNA methylation may contribute to tumor multiplicity in LS.

6 months ago

Journal

RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)

RNF43 mutation

6ms

Clinical study assessing the preliminary efficacy and safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care (ACTRN12624000588594)

P2, N=20, Not yet recruiting, Australian Genomic Cancer Medicine Centre Ltd t/a Omico

6 months ago

New P2 trial • Metastases

RNF43 (Ring Finger Protein 43)

RNF43 mutation

zamaporvint (RXC004)

7ms

Somatic mutations that affect early genetic progression and immune microenvironment in gastric carcinoma. (PubMed, Pathol Res Pract)

HRD showed a positive correlation with tumor mutational burden, which might serve as indirect evidence supporting the potential of HRD as a biomarker for GC. These findings highlighted GC's high heterogeneity and complexity and provided valuable insights into the somatic mutations that affect early genetic progression and immune microenvironment.

7 months ago

Journal • Tumor mutational burden • MSi-H Biomarker • IO biomarker

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • ARID1A (AT-rich interaction domain 1A) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • KMT2C (Lysine Methyltransferase 2C) • MUC16 (Mucin 16, Cell Surface Associated) • TTN (Titin) • FAT4 (FAT Atypical Cadherin 4) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • CSMD3 (CUB And Sushi Multiple Domains 3) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • XIRP2 (Xin Actin Binding Repeat Containing 2) • ZFHX4 (Zinc Finger Homeobox 4)

MSI-H/dMMR • HRD • ARID1A mutation • RNF43 mutation • SMAD4 mutation

7ms

Selective epigenetic alterations in RNF43 in pancreatic exocrine cells from high-fat-diet-induced obese mice; implications for pancreatic cancer. (PubMed, BMC Res Notes)

Results revealed no significant differences in methylation levels in loci between HFD- and normal-fat-diet (NFD)-fed mice, except for RNF43, a negative regulator of Wnt signaling, which showed hypermethylation in three loci. These findings indicate that, in mouse pancreatic exocrine cells, high-fat dietary obesity induced aberrant DNA methylation in RNF43 but not in other frequently mutated PC-related genes.

7 months ago

Preclinical • Journal

TP53 mutation • KRAS mutation • RNF43 mutation

7ms

Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer. (PubMed, Sci Adv)

These FBXW7-mutant Wnt/β-catenin-independent tumors are susceptible to multi-cyclin-dependent kinase inhibition. An in-depth understanding of primary resistance to anti-Wnt/β-catenin therapies allows for more appropriate patient selection and use of alternative mechanism-based therapies.

7 months ago

Journal

RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7)

FBXW7 mutation • RNF43 mutation

8ms

NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study. (PubMed, Hepatol Commun)

In summary, NGS of BC samples increased the sensitivity of detecting biliary neoplasia compared with traditional cytology. Performing NGS on BC samples may help diagnose HGD or early CCA, benefiting the timing of liver transplantation.

8 months ago

Retrospective data • Journal • Next-generation sequencing • Cytology

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • ATRX (ATRX Chromatin Remodeler) • GNAS (GNAS Complex Locus)

TP53 mutation • BRAF mutation • ATM mutation • RNF43 mutation • GNAS mutation

8ms

Ring Finger 43 Hot-spot Frameshift Mutation G659V in Colorectal Cancer Patients: Report from a Tertiary Cancer Care Hospital in North India. (PubMed, Int J Appl Basic Med Res)

To the best of our knowledge, this is the first study from North India to show the involvement of RNF43 p.G659fs variant in CRC patients. The mutation correlated with MMR protein deficiency and seems to be conferring tumorigenicity independent of the Wnt pathway.

8 months ago

Journal

RNF43 (Ring Finger Protein 43)

RNF43 mutation • RNF43 G659fs

8ms

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) (clinicaltrials.gov)

P1, N=70, Active, not recruiting, Eisai Co., Ltd. | Recruiting --> Active, not recruiting

8 months ago

Enrollment closed • Metastases

RNF43 (Ring Finger Protein 43) • APC (APC Regulator Of WNT Signaling Pathway) • AXIN1 (Axin 1) • ZNRF3 (Zinc And Ring Finger 3)

APC mutation • CTNNB1 mutation • RNF43 mutation

E7386

9ms

Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer. (PubMed, Hum Pathol)

Considering the differences in mucin phenotype and genetic alterations, different modes of tumorigenesis are assumed for CRC with BRAF V600E mutation and non-V600E mutations. These findings are important in understanding the biology and treatment strategies for BRAF-mutant CRC.

9 months ago

Journal

BRAF (B-raf proto-oncogene) • RNF43 (Ring Finger Protein 43) • APC (APC Regulator Of WNT Signaling Pathway) • MME (Membrane Metalloendopeptidase) • MUC2 (Mucin 2) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6)

BRAF V600E • APC mutation • RNF43 mutation • MUC5AC expression

9ms

Association of RNF43 Genetic Alterations With BRAFV600E and MSIhigh in Colorectal Cancer. (PubMed, JCO Precis Oncol)

Ongoing phase III clinical trials, such as BREAKWATER, should aim to incorporate broader genetic profiling to further validate the superior sensitivity of patients with RNF43-mutant, MSS BRAFV600E CRC to anti-EGFR-/BRAFi-based therapies.

9 months ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • RNF43 (Ring Finger Protein 43)

BRAF V600E • MSI-H/dMMR • BRAF V600 • RNF43 mutation • BRAF V600E + MSI-H/dMMR

9ms

Neoplastic Progression in Macroscopic Precursor Lesions of the Pancreas. (PubMed, Arch Pathol Lab Med)

The recurrent alterations described in cysts provide an opportunity for diagnosis using aspirated cyst fluid. Molecular characterization of IPMNs shows a striking spatial and mutational heterogeneity, challenging traditional models of neoplastic development and creating challenges to interpretation of cyst fluid sequencing results.

9 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • GNAS (GNAS Complex Locus) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • PRKACB (Protein Kinase CAMP-Activated Catalytic Subunit Beta)

TP53 mutation • KRAS mutation • RNF43 mutation • GNAS mutation

9ms

New insights in ubiquitin-dependent Wnt receptor regulation in tumorigenesis. (PubMed, In Vitro Cell Dev Biol Anim)

RNF43 may simultaneously play different roles in classical multistep tumorigenesis, as both wild-type and mutant RNF43 suppress the p53 pathway. We hope that the knowledge obtained from further research in RNF43 will be applied to cancer treatment in the future despite the fully unclear function of RNF43.

9 months ago

Review • Journal

RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)

TP53 mutation • RNF43 mutation

9ms

Molecular and Clinical Characterization of Oncocytic Intraductal Papillary Neoplasms of the Pancreas (USCAP 2024)

The presence of a PRKACA/B fusion appears to contribute to oncocytic morphology, but 71% of fusion-positive cases had mixed epithelial subtypes. Rare cases harbored concurrent fusion and driver mutation associated with IPMN. Though fusion-positive lesions were more commonly seen in the non-recurrence group, they also comprised >50% of cases with disease recurrence.

9 months ago

Clinical

KRAS (KRAS proto-oncogene GTPase) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • GNAS (GNAS Complex Locus) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha)

KRAS mutation • RNF43 mutation • SMAD4 deletion • GNAS mutation • KRAS deletion

OncoPanel™ Assay

10ms

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. (PubMed, BMC Med)

MSI-H status was associated with a higher TMB value and more positive PD-L1 expression in CCA tumors. Moreover, in patients with advanced CCA who received PD-1 inhibitor-based immunotherapy, MSI-H and positive PD-L1 expression were associated with improved both OS and PFS.

10 months ago

Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • KMT2D (Lysine Methyltransferase 2D) • RNF43 (Ring Finger Protein 43) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • ACVR2A (Activin A Receptor Type 2A)

PD-L1 expression • TMB-H • MSI-H/dMMR • ARID1A mutation • PBRM1 mutation • RNF43 mutation • PD-L1 expression + MSI-H/dMMR

10ms

RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells. (PubMed, Adv Sci (Weinh))

MEK and WNT inhibitors synergistically suppress the growth of RNF43-mutated pancreatic cancer cells in vitro and in vivo. Collectively, the research reveals a novel mechanism by which RNF43 inhibits B-RAF/MEK signaling to suppress tumor growth and provide a new strategy for the treatment of RNF43-inactivated pancreatic cancer.

10 months ago

Journal

BRAF (B-raf proto-oncogene) • RNF43 (Ring Finger Protein 43)

RNF43 mutation

10ms

Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer. (PubMed, Ther Adv Med Oncol)

Moreover, we observed that pMMR/MSS patients with RNF43 R117fs mutation had a higher incidence of stage IV, ⩾2 metastatic sites, low TMB, and none of them received PD-1/PD-L1 inhibitor therapy. Our findings provide the first evidence that RNF43 mutations in NTD and the R117fs variant correlate with a poorer prognosis in CRC patients, providing strategies for Wnt-targeted therapy to improve clinical efficacy.

10 months ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • RNF43 (Ring Finger Protein 43)

BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600 • TMB-L • RNF43 mutation

10ms

KEYNOTE-E86: A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (clinicaltrials.gov)

P2, N=45, Completed, Redx Pharma Plc | Active, not recruiting --> Completed

10 months ago

Trial completion • Metastases

RNF43 (Ring Finger Protein 43)

RNF43 mutation

Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)

10ms

Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review. (PubMed, Gut)

Cyst fluid CEA continues to be a useful test in the diagnosis of mucinous pancreatic cysts but does not appear as specific as previously reported. Raising the CEA threshold to 250 ng/mL to maintain specificity for differentiating mucinous from non-mucinous cysts may be considered.

10 months ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase) • RNF43 (Ring Finger Protein 43) • CEACAM5 (CEA Cell Adhesion Molecule 5) • GNAS (GNAS Complex Locus)

RNF43 mutation • GNAS mutation

11ms

Canonical Wnt signaling pathway (WSP) alterations in metastatic prostate cancer. (ASCO-GU 2024)

WSP-act prostate cancer demonstrated a pronounced upregulation of ROR1 gene expression, underscoring its potential involvement in the crosstalk between the canonical and non-canonical Wnt signaling pathways. Additionally, the augmented levels of M2 macrophages in WSP-act tumors, combined with the reported role of ROR1 in tumor immunosuppression, suggests that ROR1 may contribute to immune evasion in WSP-act mPCa. Our findings may provide rationale for developing novel therapeutic strategies targeting Wnt-activated prostate cancers.

11 months ago

MSi-H Biomarker • Metastases

RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SPOP (Speckle Type BTB/POZ Protein) • RSPO2 (R-Spondin 2)

MSI-H/dMMR • ROR1 expression • RNF43 mutation • SPOP mutation • RNF43 G659fs • CTNNB1 expression

MI Tumor Seek™

11ms

RNF43 mutation as a predictor of immunotherapeutic efficacy in colorectal cancer. (PubMed, Am J Cancer Res)

Our results suggest that RNF43 mutation may correlate with better OS in CRC patients receiving PD-1/PD-L1 inhibitors. The exact mechanisms underlying RNF43 require further investigation.

11 months ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • RNF43 (Ring Finger Protein 43) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)

PD-L1 expression • TP53 mutation • KRAS mutation • TMB-H • MSI-H/dMMR • RNF43 mutation

11ms

Identification and characterization of immunogenic neoantigens in colorectal cancer (CRC). (ASCO-GI 2024)

This is one of the largest studies to investigate the landscape of immunogenic neoantigens in CRC. We were able to identify candidate recurrent peptides with high HLA binding affinity and an association with a positive TIS signature supporting the role of neoantigens as potential cancer immunotherapy targets.

11 months ago

MSi-H Biomarker • IO biomarker

MSI (Microsatellite instability) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2D (Lysine Methyltransferase 2D) • RNF43 (Ring Finger Protein 43) • APC (APC Regulator Of WNT Signaling Pathway) • MSH3 (MutS Homolog 3) • SOX9 (SRY-Box Transcription Factor 9)

MSI-H/dMMR • APC mutation • RNF43 mutation • MSH3 mutation

11ms

LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC). (ASCO-GI 2024)

Our data show a strong association between LMTK3 gene expression and distinct molecular features and TME immune cell infiltration in CRC. These findings suggest that LMTK3 may be an important molecular factor that plays a role in determining the composition of the TME, thus targeting LMTK3 could represent a novel strategy in selected CRC subgroups.

11 months ago

MSi-H Biomarker • IO biomarker

ER (Estrogen receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • IFNG (Interferon, gamma) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • CD4 (CD4 Molecule) • CDX2 (Caudal Type Homeobox 2) • AMER1 (APC Membrane Recruitment Protein 1)

TP53 mutation • TMB-H • MSI-H/dMMR • ATM mutation • ASXL1 mutation • APC mutation • RNF43 mutation • SMAD4 mutation • MLL mutation

11ms

High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness. (ASCO-GI 2024)

Sponsored by NCI, NCI Background: Cetuximab (CTX) and Panitumumab (PMB) therapies directed at EGFR have been restricted to left-sided CRC harboring wild-type KRAS (KRASWT), limiting their utility. Our data suggest that CTX-S may predict longer survival on EGFRi, surprisingly independent of RAS/BRAF mutation status as well as tumor sidedness. Patients with high CTX-S had increased prevalence of CMS2 and harbored more APC and TP53 mutations. A strong EGFRi biomarker would likely expand the utility of EGFRi to right-sided tumors and possibly to RASMUT tumors.

11 months ago

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • APC (APC Regulator Of WNT Signaling Pathway) • RAS (Rat Sarcoma Virus)

TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • KRAS wild-type • BRAF wild-type • RAS mutation • RAS wild-type • APC mutation • RAS wild-type + BRAF wild-type • RNF43 mutation

MI Tumor Seek™

Erbitux (cetuximab) • Vectibix (panitumumab)

11ms

The impact of Wnt pathway alterations including RNF43, GNAS, CTNNB1, and APC on prognosis and potential therapeutic vulnerability in pancreatic adenocarcinoma (PDAC). (ASCO-GI 2024)

Hazard ratios and p-values were computed via Cox regression when comparing PFS within subsets that received either 1st line FOLFIRINOX (FFX) or 1st line gemcitabine/nab-paclitaxel (GA)... The presence of Wnt pathway alterations identifies a subgroup of advanced PDAC with improved PFS and OS. >

11 months ago

MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway) • GNAS (GNAS Complex Locus)

TP53 mutation • KRAS mutation • MSI-H/dMMR • PIK3CA mutation • APC mutation • RNF43 mutation

gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium

11ms

High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma. (PubMed, Hum Pathol)

Importantly, our approach, using data from genome-wide methylation profiling for analysis of overall CNV burden, can be performed on formalin-fixed and paraffin embedded PDAC tissues. Future studies should examine the prognostic value of overall CNV burden in unresectable PDAC.

11 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • KDM6A (Lysine Demethylase 6A) • GNAS (GNAS Complex Locus)

TP53 mutation • KRAS mutation • RNF43 mutation

12ms

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. (PubMed, J Clin Oncol)

These results can provide new tools to predict patient outcome and improve therapeutic decisions and trial participation in patient minorities. The molecular alterations identified in this study may direct biomarker-driven studies.

12 months ago

Journal • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43)

BRAF V600E • KRAS mutation • MSI-H/dMMR • BRAF wild-type • RAS mutation • APC mutation • RNF43 mutation

Avastin (bevacizumab) • Erbitux (cetuximab)

almost1year

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations. (PubMed, Biomed Pharmacother)

Moreover, HLA-A* 11:01-restricted T cells exhibited elevated levels of IFN-gamma, granulysin, and granzyme B, indicating their potent anti-tumor capabilities. These findings underscore the specificity and efficiency of HLA-A* 11:01-restricted T cells targeting KRAS, RNF43, TP53 mutated CCA cells, and offer valuable insights for developing immunotherapeutic strategies and therapeutic peptide-vaccines for CCA treatment.

almost 1 year ago

Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • RNF43 (Ring Finger Protein 43) • GZMB (Granzyme B) • CD40 (CD40 Molecule) • ITGAX (Integrin Subunit Alpha X) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)

TP53 mutation • KRAS mutation • RNF43 mutation • HLA-A*11

1year

Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. (PubMed, JCO Precis Oncol)

In this large, real-world multiomic characterization of age-stratified molecular differences in pancreatic ductal adenocarcinoma, YOPC is associated with a distinct molecular landscape that has prognostic and therapeutic implications.

1 year ago

Journal • BRCA Biomarker • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NRG1 (Neuregulin 1) • CD8 (cluster of differentiation 8) • SF3B1 (Splicing Factor 3b Subunit 1) • PALB2 (Partner and localizer of BRCA2) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1)

TP53 mutation • BRCA2 mutation • MSI-H/dMMR • PALB2 mutation • KRAS wild-type • RAS wild-type • CDKN2A mutation • MET mutation • NRG1 fusion • BRAF fusion • RNF43 mutation • MET fusion

1year

Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy. (PubMed, JCO Precis Oncol)

Patients with pMMR/MSS BRAFV600E-mut mCRC achieve benefit from TT versus CT independently of RNF43 mutational status, although a higher magnitude of benefit from TT is observed in RNF43-mut tumors. These findings deserve confirmation in concluded and ongoing randomized trials.

1 year ago

Journal • Mismatch repair • Metastases

RNF43 (Ring Finger Protein 43)

BRAF V600E • BRAF V600 • RNF43 mutation

Erbitux (cetuximab) • Braftovi (encorafenib) • oxaliplatin • irinotecan

1year

Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker. (PubMed, Eur J Med Res)

Our results first present the expression pattern and the mutation signature of RNF43, highlighting that RNF43 is an important prognostic biomarker in pan-cancer. Furthermore, RNF43 seems to be a critical modulator in the tumor immune microenvironment and can function as a promising biomarker for predicting the immunotherapeutic efficacy of anti-PD-1/PD-L1 treatment, and drug sensitivity in cancer treatment.

1 year ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • RNF43 (Ring Finger Protein 43)

RNF43 mutation • RNF43 expression

1year

Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma (PubMed, Zhonghua Fu Chan Ke Za Zhi)

The concordance of MMR-IHC and MSI-NGS in EC is relatively high.The discordance in a few MMR-d EC are mostly found in cases with MLH1 and (or) PMS2 protein loss or MMR protein subclonal staining caused by MLH1 gene promoter hypermethylation. In order to provide accurate molecular typing for EC patients, MLH1 gene methylation, MSI-PCR, MMR gene germline mutation and TMB should be combined to comprehensively evaluate MMR and MSI status.

1 year ago

Journal • Mismatch repair • Tumor mutational burden • Microsatellite instability • BRCA Biomarker • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • POLE (DNA Polymerase Epsilon) • MLH1 (MutL homolog 1) • LRP1B (LDL Receptor Related Protein 1B) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • RNF43 (Ring Finger Protein 43) • PMS2 (PMS1 protein homolog 2) • CREBBP (CREB binding protein) • KMT2B (Lysine Methyltransferase 2B)

TP53 mutation • TMB-H • MSI-H/dMMR • PIK3CA mutation • PTEN mutation • ARID1A mutation • RNF43 mutation • PMS2 mutation

1year

Comprehensive assessment of lymphocyte counts in colorectal cancer: Defining the optimal prognostic marker (SITC 2023)

We achieved increasingly precise and biologically relevant biomarkers by using data-driven CD3/CD8 density cutoffs and ratios, while controlling for important clinicopathologic and molecular variables in CRC. Independent validation and inclusion of other immune or stromal cell types will bring these findings closer to clinical utility in CRC.

1 year ago

IO biomarker

BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • GNAS (GNAS Complex Locus)

BRAF mutation • RNF43 mutation • SMAD4 mutation • GNAS mutation

Immunoscore®

1year

Primary cutaneous adnexal carcinoma with squamoid and microcystic glandular features distinct from microcystic adnexal carcinoma: report of a unique case with gene sequencing (ASDP 2023)

Awareness of the spectrum of findings in this category of neoplasms is key for proper diagnosis. Poster type: Poster Defense

1 year ago

Clinical

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • MTAP (Methylthioadenosine Phosphorylase) • RNF43 (Ring Finger Protein 43) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • AMER1 (APC Membrane Recruitment Protein 1)

KRAS mutation • BRAF mutation • ARID1A mutation • RNF43 mutation

1year

KEYNOTE-E86: A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (clinicaltrials.gov)

P2, N=45, Active, not recruiting, Redx Pharma Plc | Recruiting --> Active, not recruiting | N=80 --> 45 | Trial primary completion date: Jun 2023 --> Nov 2023

1 year ago

Enrollment closed • Enrollment change • Trial primary completion date • Metastases

RNF43 (Ring Finger Protein 43)

RNF43 mutation

Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)